Form 4: Regeneron EVP Marion McCourt Reports Stock Sale

Marion McCourt, EVP Commercial at Regeneron Pharmaceuticals, reports the sale of 358 shares of common stock at $967.5 per share on March 1, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Marion McCourt, an Executive Vice President at Regeneron Pharmaceuticals, reported a transaction involving the company's common stock.
• On March 1, 2024, McCourt sold 358 shares of Regeneron common stock at a price of $967.5 per share.
• The sale was executed under a pre-arranged trading plan (Rule 10b5-1(c)) adopted on February 16, 2023.
• Following the transaction, McCourt directly owns 13,431 shares and indirectly owns 158 shares through a 401(k) plan.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an executive's stock sale under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. They can be driven by various factors, including personal financial planning and diversification. The use of a pre-arranged trading plan (Rule 10b5-1) is a common practice to avoid accusations of insider trading.

Comparison to Industry Standards

• Executive stock sales are a normal part of compensation packages in publicly traded companies like Regeneron.
• Companies such as Amgen, Gilead Sciences, and Biogen also see similar transactions from their executives.
• The use of 10b5-1 plans is a standard practice among executives to ensure compliance with insider trading regulations, similar to practices at Pfizer and Merck.

Stakeholder Impact

• The stock sale by an executive could have a minor psychological impact on shareholders, but is unlikely to have a significant material impact due to the relatively small number of shares involved and the pre-planned nature of the transaction.
• The transaction does not directly impact employees, customers, suppliers, or creditors.

Key Dates